Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DHIMAN BASU

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1336266964
CMS profile
60261
Location
COLLEYVILLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$312,538.35

778 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 13 of 16; records 601–650 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DHIMAN BASU

NPI 1336266964 · CMS profile ID 60261

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

COLLEYVILLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 13 of 16; records 601–650 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=13#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DHIMAN BASU, NPI 1336266964, CMS profile ID 60261. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 16; records 601–650 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DHIMAN BASU, NPI 1336266964, CMS profile ID 60261. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 16; records 601–650 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DHIMAN BASU, NPI 1336266964, CMS profile ID 60261, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 13 of 16; records 601–650 of 778 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336266964?year=2019&recipient=provider&page=13#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

778 matching records · $312,538.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 778 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 601–650 of 778.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.3004/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671976525 CMS
Horizon Therapeutics plc $3.5804/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691329469 CMS
Horizon Therapeutics plc $7.8704/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691329473 CMS
Celgene Corporation $50.0004/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672778441 CMS
AbbVie, Inc. $640.6004/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825735 CMS
AbbVie, Inc. $97.8104/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825743 CMS
AbbVie, Inc. $14.8004/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825811 CMS
AbbVie, Inc. $14.8004/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825813 CMS
AbbVie, Inc. $14.8004/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825815 CMS
AbbVie, Inc. $14.8004/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825817 CMS
Lilly USA, LLC $21.0304/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657784921 CMS
UCB, Inc. $43.1604/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688270041 CMS
GENZYME CORPORATION $16.6604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693982513 CMS
Amgen Inc. $18.7704/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662303985 CMS
E.R. Squibb & Sons, L.L.C. $3.2004/02/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651263247 CMS
Lilly USA, LLC $1,800.0004/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657777443 CMS
Lilly USA, LLC $675.0004/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657784903 CMS
Mallinckrodt Enterprises LLC $1,700.0004/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704769901 CMS
AbbVie, Inc. $687.5003/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825733 CMS
Genentech USA, Inc. $16.0003/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681285835 CMS
Lilly USA, LLC $18.0603/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657770455 CMS
Mallinckrodt Enterprises LLC $1.5603/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704769889 CMS
Mallinckrodt Enterprises LLC $10.0003/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704769891 CMS
Mallinckrodt Enterprises LLC $19.4603/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704769893 CMS
Mallinckrodt Enterprises LLC $33.5603/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704769895 CMS
Mallinckrodt Enterprises LLC $35.9603/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704769897 CMS
Mallinckrodt Enterprises LLC $41.7603/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704769899 CMS
E.R. Squibb & Sons, L.L.C. $9.5903/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651263255 CMS
E.R. Squibb & Sons, L.L.C. $3.3003/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651263257 CMS
Lilly USA, LLC $10.6003/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657763575 CMS
Lilly USA, LLC $35.9603/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657763577 CMS
Lilly USA, LLC $67.1203/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657770441 CMS
SANOFI-AVENTIS U.S. LLC $40.5903/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693983275 CMS
AbbVie, Inc. $7.5703/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825707 CMS
Lilly USA, LLC $14.1403/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657763573 CMS
Lilly USA, LLC $129.0003/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657766977 CMS
Lilly USA, LLC $61.8303/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657773995 CMS
Lilly USA, LLC $37.1203/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657777439 CMS
Lilly USA, LLC $17.8103/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657777441 CMS
Lilly USA, LLC $33.5603/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657784901 CMS
Novartis Pharmaceuticals Corporation $114.0303/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658907269 CMS
PFIZER INC. $5.9403/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671894667 CMS
GENZYME CORPORATION $17.9303/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694015787 CMS
AbbVie, Inc. $45.1103/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647825739 CMS
Amgen Inc. $20.2703/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662303969 CMS
Lilly USA, LLC $16.4803/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657766989 CMS
Regeneron Healthcare Solutions, Inc. $35.2503/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673337715 CMS
Regeneron Healthcare Solutions, Inc. $379.7703/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673337719 CMS
Horizon Therapeutics plc $5.7103/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691329467 CMS
Celgene Corporation $63.5003/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672765857 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $312,538.35 778
PY2020 $119,148.16 392
PY2021 $230,749.31 545
PY2022 $265,367.17 669
PY2023 $315,726.03 722
PY2024 $296,584.35 698
PY2025 $258,677.53 593

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $411,062.83 52
PY2024 Recipient $114.46 1
PY2024 Principal investigator $257,835.14 42
PY2023 Principal investigator $473,106.02 96
PY2022 Principal investigator $889,967.32 177
PY2021 Recipient $378.10 1
PY2021 Principal investigator $886,971.42 112
PY2020 Recipient $2,874.16 3
PY2020 Principal investigator $874,310.45 106
PY2019 Recipient $3,639.50 1
PY2019 Principal investigator $614,123.64 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $11,500.00 12/09/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINIC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187887550
Principal investigator 1 ABBVIE INC. $4,455.90 12/04/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202527318
Principal investigator 1 ABBVIE INC. $1,856.03 12/04/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202527320
Principal investigator 1 Janssen Research & Development, LLC $13,658.00 11/27/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RE
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175414442
Principal investigator 1 GlaxoSmithKline, LLC. $16,027.20 11/05/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192135287
Principal investigator 1 ABBVIE INC. $2,187.45 11/04/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202520423
Principal investigator 1 ABBVIE INC. $6,047.69 11/04/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202520425
Principal investigator 1 ABBVIE INC. $1,586.35 10/09/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202514819
Principal investigator 1 Daiichi Sankyo Company LTD $244.80 09/08/2025 Non-covered Recipient Entity
Precision Comprehensive Clinical Research Solutions
DS7011-107 No dispute reported 06/30/2026 1186252421
Principal investigator 1 Daiichi Sankyo Inc. $244.80 09/08/2025 Non-covered Recipient Entity
Precision Comprehensive Clinical Research Solutions
DS7011-107 No dispute reported 06/30/2026 1223376249
Principal investigator 1 ABBVIE INC. $3,780.90 09/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202507541
Principal investigator 1 ABBVIE INC. $2,113.20 09/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507543
Principal investigator 1 GlaxoSmithKline, LLC. $2,564.10 09/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192135316
Principal investigator 1 GlaxoSmithKline, LLC. $13,100.00 08/26/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192135294
Principal investigator 1 ABBVIE INC. $3,068.91 08/05/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202501778
Principal investigator 1 ABBVIE INC. $2,431.80 08/05/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202501866
Principal investigator 1 GlaxoSmithKline, LLC. $4,845.60 08/01/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192135301
Principal investigator 1 Daiichi Sankyo Company LTD $2,864.00 07/16/2025 Non-covered Recipient Entity
Precision Comprehensive Clinical Research Solutions
DS7011-107 No dispute reported 06/30/2026 1186252423
Principal investigator 1 Daiichi Sankyo Inc. $526.00 07/16/2025 Non-covered Recipient Entity
Precision Comprehensive Clinical Research Solutions
DS7011-107 No dispute reported 06/30/2026 1223376243
Principal investigator 1 Daiichi Sankyo Inc. $1,060.00 07/16/2025 Non-covered Recipient Entity
Precision Comprehensive Clinical Research Solutions
DS7011-107 No dispute reported 06/30/2026 1223376245
Principal investigator 1 Daiichi Sankyo Inc. $1,278.00 07/16/2025 Non-covered Recipient Entity
Precision Comprehensive Clinical Research Solutions
DS7011-107 No dispute reported 06/30/2026 1223376247
Principal investigator 1 ABBVIE INC. $268.35 07/02/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202494457
Principal investigator 1 ABBVIE INC. $2,227.95 07/02/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494789
Principal investigator 1 GlaxoSmithKline, LLC. $2,527.20 07/02/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192129887
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,671.21 06/09/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE RESEARCH
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190309244
Principal investigator 1 GlaxoSmithKline, LLC. $4,736.70 06/04/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192129875
Principal investigator 1 ABBVIE INC. $2,227.95 06/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202488801
Principal investigator 1 ABBVIE INC. $2,842.16 06/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202489231
Principal investigator 1 GlaxoSmithKline, LLC. $8,588.70 05/09/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192135308
Principal investigator 1 ABBVIE INC. $3,109.73 05/06/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202481387
Principal investigator 1 ABBVIE INC. $2,668.35 05/06/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202481389
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,242.84 04/17/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185550143
Principal investigator 1 ABBVIE INC. $3,346.35 04/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202473309
Principal investigator 1 ABBVIE INC. $930.48 04/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202473313
Principal investigator 1 GlaxoSmithKline, LLC. $2,677.50 03/07/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192129881
Principal investigator 1 ABBVIE INC. $5,548.81 03/06/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202457178
Principal investigator 1 ABBVIE INC. $2,240.15 03/06/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202457182
Principal investigator 1 UCB SA $9,750.00 03/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659559
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,148.28 02/27/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus No dispute reported 06/30/2026 1190311089
Principal investigator 1 ABBVIE INC. $736.05 02/05/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202444725
Principal investigator 1 ABBVIE INC. $2,690.10 02/05/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202445881
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,157.00 01/28/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190311087
Principal investigator 1 Eli Lilly and Company $1,362.39 01/27/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINIC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187887628
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,687.22 01/21/2025 Non-covered Recipient Entity
Precision Comprehensive Clinical Research Solutions
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235994569
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,404.46 01/15/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE RESEARCH
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus No dispute reported 06/30/2026 1190309248
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,820.14 01/14/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190311085
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $16,450.00 01/13/2025 Non-covered Recipient Entity
HERITAGE RHEUMATOLOGY AND ARTHRITIS CARE
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) No dispute reported 06/30/2026 1214124184
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,888.77 01/09/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE RESEARCH
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190309246
Principal investigator 1 Eli Lilly and Company $90,824.00 01/07/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINIC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187887944
Principal investigator 1 AstraZeneca Pharmaceuticals LP $72,234.67 01/03/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL RESEARCH SOLUTIONS, LLC
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185550145
Principal investigator 1 ABBVIE INC. $4,833.29 01/02/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202435865
Principal investigator 1 ABBVIE INC. $3,781.30 01/02/2025 Non-covered Recipient Entity
PRECISION COMPREHENSIVE CLINICAL
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202435878